KB Degn, B Brock, CB Juhl, CB Djurhuus, J … - Diabetes, 2004 - Am Diabetes Assoc This study assessed whether glucose-dependent insulin secretion and overall
counterregulatory response are preserved during hypoglycemia in the presence of
exenatide. Twelve healthy fasted volunteers were randomized in a ... Cited by 122 - Related articles - BL Direct - All 6 versions
MS Fineman, LZ Shen, K Taylor, DD Kim, AD … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 112 - Related articles - BL Direct - All 3 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1
analogues have actions with the potential to significantly improve glycemic
control in patients with diabetes. Evidence suggests that these agents use ... Cited by 185 - Related articles - All 7 versions
OG Kolterman, DD Kim, L Shen, JA Ruggles, … - American Journal of Health-System Pharmacy, 2005 - ASHP R UGGLES , P H .D., is Associate Director Medical Writing, Medical Af- fairs; L
ORETTA L. N IELSEN , P H .D., is Senior Medical Writer, Medical Affairs; M ARK
S. F INEMAN , BS, is Senior Director, Clinical Affairs; and A LAIN D. B ... Cited by 139 - Related articles - All 5 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes
population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel
glucose-dependent insulinotropic agent, exhibited notable antidiabetic ... Cited by 275 - Related articles - BL Direct - All 6 versions
- ►endojournals.org JM Egan, AR Clocquet, D Elahi - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Exendin-4 is a potent and long-acting agonist of the glucagon-like peptide-1
(GLP-1) receptor. GLP-1 is an insulinotropic gut peptide and is being evaluated
for the regulation of plasma glucose in type 2 diabetes. The purpose of the ... Cited by 161 - Related articles - BL Direct - All 4 versions
- ►endojournals.org F Fehse, M Trautmann, JJ Holst, AE Halseth … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Context: First-phase insulin secretion (within 10 min after a sudden rise in
plasma glucose) is reduced in type 2 diabetes mellitus (DM2). The incretin
mimetic exenatide has glucoregulatory activities in DM2, including glucose- ... Cited by 122 - Related articles - BL Direct - All 4 versions
- ►physiology.org CMB Edwards, SA Stanley, R Davis, AE Brynes … - American Journal of Physiology- Endocrinology And …, 2001 - Am Physiological Soc Exendin-4 is a long-acting potent agonist of the glucagon-like peptide 1 (GLP-1)
receptor and may be useful in the treatment of type 2 diabetes and obesity. We
examined the effects of an intravenous infusion of exendin-4 (0.05 pmol · ... Cited by 230 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum
fructosamine relative to placebo (P ≤ 0.004). Mean reductions ranged from 39
to 46 μmol/l. All AC2993 groups had reductions in HbA 1c ranging from 0.7 ... Cited by 230 - Related articles - BL Direct - All 10 versions
DG Parkes, R Pittner, C Jodka, P Smith, A … - Metabolism, 2001 - Elsevier This study compares in vitro effects of exendin-4 and glucagon-like peptide
(GLP)-1 on basal and glucose-stimulated insulin release from isolated rat islets
and in vivo insulinotropic actions of exendin-4 and GLP-1 after an ... Cited by 130 - Related articles - BL Direct - All 6 versions
